New Advances in Cancer Metabolic Reprogramming: From Molecular Mechanisms to Therapeutic Strategies

Dear Colleagues,

Cancer metabolic reprogramming is a defining hallmark of malignant transformation, enabling tumor cells to sustain rapid proliferation under nutrient-limited and hypoxic conditions. The Warburg effect—preferential aerobic glycolysis—was among the earliest recognized metabolic adaptations in cancer; however, extensive research has revealed a far more complex landscape. Reprogrammed tumor cells exploit glutamine catabolism, de novo fatty acid synthesis, and one-carbon metabolism while dynamically remodeling mitochondrial function to support biosynthetic demands, redox homeostasis, and epigenetic regulation. This Special Issue aims to consolidate recent advances in our understanding of cancer metabolic reprogramming, spanning molecular mechanisms, regulatory networks, and their implications for therapeutic intervention.

Potential topics include but are not limited to:

(i) Oncogene- and tumor suppressor-driven metabolic rewiring;

(ii) Metabolic crosstalk within the tumor microenvironment;

(iii) The role of mitochondrial dynamics and TCA cycle remodeling in cancer progression;

(iv) Metabolite-mediated epigenetic regulation;

(v) Metabolic adaptation underlying drug resistance;

(vi) Emerging therapeutic strategies targeting metabolic vulnerabilities;

(vii) Immune metabolic changes in cancer.

By integrating multi-omics approaches with functional studies, this Special Issue will deepen our understanding of the metabolic dependencies of cancer cells and accelerate the translation of metabolic targets into novel oncological treatments.

Dr. Songyeon Ahn
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.